Suppr超能文献

可溶性环氧化物水解酶抑制物可减少肥胖小鼠的食物摄入并增加代谢率。

Inhibition of soluble epoxide hydrolase reduces food intake and increases metabolic rate in obese mice.

机构信息

Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State St., Jackson, MS 39216-4505, United States.

出版信息

Nutr Metab Cardiovasc Dis. 2012 Jul;22(7):598-604. doi: 10.1016/j.numecd.2010.10.017. Epub 2010 Dec 28.

Abstract

BACKGROUND AND AIMS

This study evaluated the responses to soluble epoxide hydrolase (s-EH) inhibition, an essential enzyme in the metabolism of arachidonic acid, on food intake, body weight and metabolic parameters in mice fed a high fat-high fructose diet (HFD) for 10 weeks.

METHODS AND RESULTS

After 5 weeks of HFD, mice were divided into two groups: 1) s-EH inhibitor (AR9281, 200mg/kg/day by gavage twice daily), and 2) vehicle (0.3ml per gavage). Food intake, body weight, oxygen consumption (VO(2)), carbon dioxide production (VCO(2)), respiratory quotient (RQ), and motor activity were measured weekly for more 5 weeks. HFD increased body weight (37±1 vs. 26±1g), and plasma of glucose (316±8 vs. 188±27mg/dl), insulin (62.1±8.1 vs. 15.5±5.0μU/ml), and leptin levels (39.4±3.6 vs. 7.5±0.1ng/ml) while reducing VO(2), VCO(2) and motor activity. s-EH inhibition for 5 weeks decreased caloric intake by ~32% and increased VO(2) by ~17% (42.8±1.4 vs. 50.2±1.5ml/kg/min) leading to significant weight loss. Inhibition of s-EHi also caused significant reductions in plasma leptin levels and visceral fat content. Uncoupling protein 1 (UCP1) content in brown adipose tissue was also elevated by ~50% during s-EH inhibition compared to vehicle treatment.

CONCLUSION

These results suggest that s-EH inhibition with AR9281 promotes weight loss by reducing appetite and increasing metabolic rate, and that increased UCP1 content may contribute to the increase in energy expenditure.

摘要

背景和目的

本研究评估了在喂食高脂肪高果糖饮食(HFD)10 周的小鼠中,对可溶型环氧水解酶(s-EH)抑制(一种花生四烯酸代谢的必需酶)的反应,以观察其对食物摄入、体重和代谢参数的影响。

方法和结果

在 HFD 喂养 5 周后,将小鼠分为两组:1)s-EH 抑制剂(AR9281,每天两次通过灌胃 200mg/kg),和 2)载体(每次灌胃 0.3ml)。在接下来的 5 周内每周测量食物摄入、体重、耗氧量(VO₂)、二氧化碳生成量(VCO₂)、呼吸商(RQ)和运动活动。HFD 增加了体重(37±1 比 26±1g),并增加了血浆葡萄糖(316±8 比 188±27mg/dl)、胰岛素(62.1±8.1 比 15.5±5.0μU/ml)和瘦素水平(39.4±3.6 比 7.5±0.1ng/ml),同时降低了 VO₂、VCO₂和运动活动。5 周的 s-EH 抑制减少了约 32%的热量摄入,并增加了约 17%的 VO₂(42.8±1.4 比 50.2±1.5ml/kg/min),导致显著的体重减轻。s-EHi 的抑制还导致血浆瘦素水平和内脏脂肪含量的显著降低。与载体处理相比,s-EH 抑制还使棕色脂肪组织中的解偶联蛋白 1(UCP1)含量增加了约 50%。

结论

这些结果表明,用 AR9281 抑制 s-EH 通过减少食欲和增加代谢率来促进体重减轻,而 UCP1 含量的增加可能有助于增加能量消耗。

相似文献

引用本文的文献

本文引用的文献

2
Correlates of weight loss in persons with metabolic syndrome.代谢综合征患者体重减轻的相关因素。
Prev Med. 2009 Nov;49(5):396-401. doi: 10.1016/j.ypmed.2009.09.012. Epub 2009 Sep 15.
4
Eicosanoids and renal damage in cardiometabolic syndrome.二十碳类化合物与心脏代谢综合征中的肾损伤
Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):165-74. doi: 10.1517/17425255.4.2.165.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验